PROIBS US Distribution Agreement

Key points

• Immuron to distribute PROIBS® in the U.S. through Calmino group AB
• PROIBS® targets U.S. digestive/gut health supplement market
• Product already available in Australia, with positive user feedback
• PROIBS® is a European certified medical device
• Backed by science and recommended by physicians and dietitians

Full summary

Immuron Limited, an Australian biopharmaceutical company, has executed an exclusive distribution agreement for its product PROIBS® in the United States with Calmino group AB. PROIBS® is a medical device used for abdominal pain, bloating, and unsettled bowel movements. The U.S. digestive/gut health supplement market is valued at $4.16 billion. The product has already been launched in Australia and has received positive feedback from users. Immuron's Chief Commercial Officer, Flavio Palumbo, highlighted the potential of PROIBS® to improve daily life for users.

Outlook

Immuron aims to expand its digestive health product portfolio in the U.S. with the introduction of PROIBS®.